Lumiclib 200 mg Tablet
Brand Name: Lumiclib
Molecule: Ribociclib
Strength: 200 mg
Quantity: 21 Tablets
Form: Tablet
Packaging Type: Bottle
Manufacturer/Marketed By: Azista
Country of Origin: Bhutan
Please fill in the details below, and we’ll get back to you as soon as possible
Similar Products:
| Image | Product | Manufacturer / Marketed By | Price |
|---|---|---|---|
 | LuciRibo 200 mg Tablet | Lucius Pharma | Ask for Price |
| Ribotix 200 mg Tablet | Beacon Pharma | Ask for Price |
| Kisqali 200 mg Tablet | Novartis | Ask for Price |
Description
Lumiclib 200 mg Tablet is an oral anti-cancer medicine containing Ribociclib 200mg, a targeted therapy used in the treatment of certain types of advanced breast cancer. It belongs to a group of medicines known as CDK4/6 inhibitors (cyclin-dependent kinase inhibitors). Lumiclib 200 mg Tablet is commonly prescribed for patients diagnosed with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. It is typically used in combination with endocrine (hormonal) therapy such as aromatase inhibitors or fulvestrant, depending on the patient’s treatment plan. Unlike traditional chemotherapy, Ribociclib works by targeting specific proteins that regulate cancer cell division. By interfering with these proteins, Lumiclib helps slow down the growth and spread of cancer cells. Treatment with Ribociclib 200mg should always be guided by an oncologist, and therapy decisions ar
Benefits
Key clinically relevant benefits of Lumiclib 200 mg Tablet include:
-
Targets CDK4/6 proteins involved in cancer cell division
-
Helps delay disease progression when combined with hormonal therapy
-
Oral administration allows convenient outpatient treatment
-
Designed specifically for HR-positive, HER2-negative breast cancer
-
Supported by clinical studies in advanced breast cancer management
Treatment response varies from person to person and depends on overall health and tumor characteristics.
Indications and Usage
Lumiclib 200 mg Tablet (Ribociclib 200mg) is indicated for:
-
Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer
-
Use in combination with:
-
An aromatase inhibitor as initial endocrine-based therapy
-
Fulvestrant in patients with disease progression after endocrine therapy
-
-
Premenopausal or perimenopausal women (in combination with ovarian suppression therapy, if indicated)
This medicine is not intended for HER2-positive breast cancer or triple-negative breast cancer. Hormone receptor testing is required before starting treatment.
How it Works
Ribociclib 200mg works by blocking two important proteins called CDK4 and CDK6. These proteins help control how cells grow and divide.
In HR-positive breast cancer, cancer cells often rely on hormone signals and cell-cycle proteins to multiply. Lumiclib 200 mg Tablet slows cancer growth by:
-
Inhibiting CDK4/6 activity
-
Preventing cancer cells from progressing through the cell cycle
-
Reducing uncontrolled cell division
By combining Ribociclib with hormone therapy, doctors can target both hormone-driven growth and cell-cycle progression, providing a more comprehensive treatment approach.
Dosage & Administration
-
Typical starting dose: 600 mg daily (usually taken as three 200 mg tablets)
-
Schedule: Once daily for 21 consecutive days, followed by 7 days off (28-day cycle)
-
Route: Oral
Lumiclib 200 mg Tablet should be swallowed whole with water and can be taken with or without food.
Dose adjustments may be required depending on side effects, liver function, blood counts, or other clinical factors. Always follow your oncologist’s instructions and never change the dose without medical guidance.
Side Effects
Like all anti-cancer medicines, Ribociclib 200mg may cause side effects.
Common Side Effects
-
Low white blood cell count (neutropenia)
-
Nausea
-
Fatigue
-
Hair thinning
-
Diarrhea or constipation
-
Headache
Serious Side Effects
-
Severe neutropenia (risk of infection)
-
Liver function abnormalities
-
QT interval prolongation (heart rhythm changes)
-
Severe allergic reactions
Regular blood tests are required to monitor blood counts and liver function during treatment.
Seek immediate medical attention if you develop fever, severe weakness, jaundice, chest pain, or irregular heartbeat.
Warning and Precaution
Before starting Lumiclib 200 mg Tablet, inform your doctor about:
Blood Count Monitoring
Ribociclib can lower white blood cell counts. Routine blood tests are essential to monitor for neutropenia.
Liver Function
Liver enzymes should be monitored before and during treatment.
Heart Monitoring
This medicine may affect heart rhythm (QT prolongation). ECG monitoring may be required, especially in patients with pre-existing heart conditions.
Pregnancy and Breastfeeding
-
May cause harm to an unborn baby
-
Effective contraception is required during treatment
-
Breastfeeding is not recommended during therapy
Drug Interactions
Ribociclib may interact with:
-
Strong CYP3A inhibitors or inducers
-
Certain antibiotics and antifungals
-
Heart rhythm–affecting medicines
Always provide your oncologist with a complete list of medications and supplements.
FAQ
What is Lumiclib 200 mg used for?
Lumiclib 200 mg Tablet is used for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.
Is Ribociclib chemotherapy?
No. Ribociclib 200mg is a targeted therapy known as a CDK4/6 inhibitor. It works differently from traditional chemotherapy.
How is Lumiclib taken?
It is usually taken once daily for 21 days, followed by a 7-day break in a 28-day cycle, as prescribed by your oncologist.
Will I need regular tests during treatment?
Yes. Blood tests, liver function tests, and sometimes ECG monitoring are required to ensure safety.
Can Lumiclib be taken alone?
It is generally prescribed in combination with hormonal therapy, not as a standalone treatment.
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
READ MORE »May 6, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.